NCT06299033View on ClinicalTrials.gov

A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

December 30, 2025

Conditions
Chronic Ischemic Stroke
Interventions
DRUG

hNPC01

hNPC01, human forebrain neural progenitor cell product, intracerebral injection

Trial Locations (1)

Unknown

RECRUITING

XiangYa Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Hopstem Biotechnology Inc.

INDUSTRY